Toceranib(SU 11654; PHA 291639)|cas 356068-94-5| DC Chem|Supplier|Price|Buy  

Toceranib(SU 11654; PHA 291639)|cas 356068-94-5| DC Chem|Supplier|Price|Buy

DC Chemicals Supply: Toceranib(SU 11654; PHA 291639)|cas 356068-94-5,Purity: >98% ,Cat No. DC7329, In stock.

Contact: website:www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642798；

Toceranib(SU 11654; PHA 291639)|cas 356068-94-5 ,Synonym: SU 11654; PHA 291639; SU11654; SU-11654; PHA-291639; PHA291639  ,Chemical name: 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide ,Molecular Formula: C22H25FN4O2 ,MW: 396.457903

Toceranib(SU 11654; PHA 291639), cas 356068-94-5,Purity: >98%, Best Price and quality from DC Chemicals. Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.

Toceranib (formerly known as SU11654)  is a receptor tyrosine kinase inhibitor and is used in the treatment of canine mast cell tumor also called mastocytoma. Toceranib is the only dog-specific anti-cancer drug approved by the U.S. Food and Drug Administration.  It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654, a sister compound to SU11248, which was later approved for human therapies as Sutent. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.